Sydney, Jan 13, 2026, 17:15 AEDT — After-hours
CSL Ltd shares dipped 1.0% to finish at A$173.32 on Tuesday, erasing a 0.46% gain from Monday and underperforming the broader Australian market. The stock fluctuated between A$173.32 and A$175.86 after kicking off at A$175.01, with roughly 683,000 shares traded. 1
The S&P/ASX 200 closed 0.56% higher, boosted by advances in gold, metals, mining, and materials shares, according to a market wrap from Investing.com. 2
The underperformance is pressing because investors are still grappling with last year’s reset: CSL cut its FY26 revenue and profit forecasts and postponed the spin-off of Seqirus, its flu vaccine division, after U.S. flu vaccination rates dropped more than anticipated. “We have seen a greater decline in influenza vaccination rates in the U.S. than we expected,” CEO Paul McKenzie told shareholders. Chairman Brian McNamee described the collapse as “remarkable.” 3
Tuesday brought no fresh updates to sway the discussion. CSL’s investor page lists its latest ASX filing as the Jan. 9 securities cessation notice. 4
There were signs of rotation in the market, with materials standing out as one of the stronger groups while some defensive sectors lagged, according to a Market Index live blog during the session.
Other major healthcare stocks fared better. Cochlear inched up 0.23%, while ResMed added roughly 0.54%, based on delayed quotes from Intelligent Investor. 5
CSL has been moving forward with a restructure after putting its demerger plans on hold. In August 2025, it announced plans to slash its workforce by up to 15% and to relaunch an on-market share buyback, aiming to repurchase A$750 million worth of shares in fiscal 2026. 6
The immediate challenge lies in execution. Any further slip in U.S. vaccination demand, delays in cost savings, or softer pricing for plasma-derived therapies could tighten margins and make investors wary.
With the market shut, all eyes shift to CSL’s upcoming event: the 2026 half-year results webcast set for 10 a.m. on Feb. 11 (AEDT). Traders will hunt for fresh details on guidance, updates on the Seqirus separation, and how quickly buybacks are progressing. 7
